UBS Assumes and Upgrades Bristol-Myers Squibb Co. (BMY) at Buy

January 7, 2026 3:05 AM EST Send to a Friend
UBS analyst Michael Yee assumes coverage on Bristol-Myers Squibb Co. (NYSE: BMY) with a Buy rating from Neutral and a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login